Trinity Annual Drug Index
Evaluating the Commercial Performances of Novel Drugs Approved in 2020
Home / Intelligence / White Papers / Trinity Annual Drug Index
This report, the sixth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the commercial performance over three years of novel drugs approved by the FDA in 2020, with commercial, therapeutic value and R&D investment scores for each. 2020 saw 58 unique drug and biologic approvals, of which the majority were Oncology (29%) followed by Neurology (16%). In this report we describe the notable themes and trends within the industry and take a deeper look into a few products with outstanding performance. The COVID-19 pandemic, which swept the globe in 2020, brought unprecedented challenges and disruptions to the pharmaceutical industry, reshaping priorities and accelerating research efforts towards finding innovative solutions.
Interested in hearing expert discussion on this white paper?
View our on-demand webinar.
Complete the form below to access the full white paper
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
White Papers
Moving the Needle: Lessons from the 2023 Launch Class
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023). This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior). The needle is moving.
Read More
Briefs
The “Molecular Optimizer” Archetype: A Strategy for First-Launch Companies to Streamline Their Path to Market
The “molecular optimizer” archetype is a strategy utilized by first-launch companies to optimize existing molecules when developing their first product. Companies using this approach tend to be small and emerging biotech firms that are seeking a foothold to enter the market. The primary benefit of this approach is that the method offers a higher probability […]
Read More
Webinars
Picking Winners: Portfolio Management for a New Era
Available On Demand
Did you know 62% of products launched between September 2019 and December 2021 underperformed expectations in the first year of launch? What is going wrong, and how can we get it right? Join Trinity Life Sciences for a thought-provoking webinar to dive into the first white paper in our Industry Impact Series, Picking Winners: Portfolio Management for […]
Watch Now